公开(公告)号：US08871735B2

公开(公告)日：2014-10-28

申请号：US13668897

申请日：2012-11-05

Applicant: University of Medicine and Dentistry of New Jersey

Inventor： Stephen F. Vatner ,  Dorothy E. Vatner

IPC: A01N43/04 ,  A61K31/70 ,  A61K31/7076

CPC classification number: A61K31/7076

Abstract: The invention provides a method of reducing infarct size and/or limiting, decreasing and/or inhibiting reperfusion injury and/or ameliorating heart failure in a patient comprising administering a pharmaceutically effective amount of at least one compound capable of inhibiting AC5 to the patient. The compound capable of inhibiting AC5 is particularly effective when administered during or after reperfusion in patients suffering from an ischemic injury.

Abstract translation: 本发明提供了一种降低梗死面积和/或限制，减少和/或抑制患者的再灌注损伤和/或改善心力衰竭的方法，包括向患者施用药学有效量的至少一种能够抑制AC5的化合物。 能够抑制AC5的化合物在再灌注期间或之后在患有缺血性损伤的患者中施用时特别有效。

公开(公告)号：US20140243381A1

公开(公告)日：2014-08-28

申请号：US13774231

申请日：2013-02-22

Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY

Inventor： Jeffrey D. Laskin ,  Diane E. Heck ,  Geraldine Guillon ,  Thomas Finetti ,  Angela Hunter ,  Christophe Guillon ,  Robert D. Rapp ,  Anna T. Vetrano ,  Ned D. Heindel

IPC: C07D409/04 ,  C07D409/12 ,  C07D405/04 ,  C07D409/14 ,  C07D405/14

CPC classification number: C07D409/04 ,  A61K31/4196 ,  C07D405/04 ,  C07D405/14 ,  C07D409/12 ,  C07D409/14 ,  Y02A50/473

Abstract: Nitric oxide biosynthesis-inhibiting anti-inflammatory and anti-microbial compounds of Formula (3) and Formula (4) wherein R1 and R2 are independently selected from optionally substituted thienyl, optionally substituted furyl, optionally substituted —CH═CH-thienyl and optionally substituted provided that R2 is substituted with as nitro group Treatment methods utilizing the compounds, and methods of synthesis of the compounds are also disclosed.

Abstract translation: 式（3）和式（4）的一氧化氮生物合成抑制性抗炎和抗微生物化合物，其中R 1和R 2独立地选自任选取代的噻吩基，任选取代的呋喃基，任选取代的-CH = CH-噻吩基和任选取代的 条件是R2被硝基取代。还公开了利用该化合物的处理方法和化合物的合成方法。

公开(公告)号：US20130302889A1

公开(公告)日：2013-11-14

申请号：US13939986

申请日：2013-07-11

Applicant: Philadelphia Health and Education Corporation ,  University of Medicine and Dentistry of New Jersey

Inventor： Ira B. Black ,  Dale L. Woodbury ,  Darwin J. Prockop ,  Emily Schwarz

IPC: C12N5/0793 ,  C12N15/85

CPC classification number: C12N15/85 ,  A61K31/045 ,  A61K31/10 ,  A61K31/19 ,  A61K31/198 ,  A61K31/375 ,  A61K35/12 ,  A61K48/00 ,  C12N5/0619 ,  C12N2500/38 ,  C12N2500/90 ,  C12N2501/815 ,  C12N2501/999 ,  C12N2506/1353

Abstract: The present invention relates to methods of inducing differentiation of mammalian bone marrow stromal cells into neuronal cells by contacting marrow stromal cells with a neuronal differentiation-inducing compounds. Neuronal differentiation-inducing compounds of the invention include anti-oxidants such as, but not limited to, beta-mercaptoethanol, dimethylsulfoxide, butylated hydroxyanisole, butylated hydroxytoluene, ascorbic acid, dimethylfumarate, and n-acetylcysteine. Once induced to differentiate into neuronal cells, the cells can be used for cell therapy, gene therapy, or both, for treatment of diseases, disorders, or conditions of the central nervous system.

Abstract translation: 本发明涉及通过使骨髓基质细胞与神经元分化诱导化合物接触来诱导哺乳动物骨髓基质细胞分化为神经细胞的方法。 本发明的神经元分化诱导化合物包括抗氧化剂，例如但不限于β-巯基乙醇，二甲基亚砜，丁基化羟基苯甲醚，丁基化羟基甲苯，抗坏血酸，富马酸二甲酯和正乙酰半胱氨酸。 一旦诱导分化为神经元细胞，细胞可用于细胞治疗，基因治疗或两者，用于治疗中枢神经系统的疾病，病症或病症。

公开(公告)号：US20130065866A1

公开(公告)日：2013-03-14

申请号：US13670873

申请日：2012-11-07

Applicant: University of Medicine and Dentistry of New Jersey

Inventor： Kenneth Markowitz ,  Evros Vassiliou

IPC: A61K31/202 ,  A61K31/192 ,  A61K47/04 ,  A61K47/46 ,  A61K31/155 ,  A61K31/5383 ,  C07C69/157 ,  C07C57/30 ,  C07C57/03 ,  C12Q1/02 ,  C12Q1/68 ,  G01N33/566 ,  A61P29/00 ,  A61P31/00 ,  A61P1/02 ,  A61K31/616

CPC classification number: A61K31/165 ,  A61K9/006 ,  A61K9/1611 ,  A61K31/192 ,  A61K31/202 ,  A61K31/616 ,  G01N33/6863 ,  G01N33/94

Abstract: The present invention is a dentinal drug delivery composition composed of cationic and/or neutral porous particles containing an effective amount of a therapeutic agent, a method for using the dentinal drug delivery to provide a dental treatment, and a method for identifying anti-inflammatory agents capable of diffusing through dentin.

Abstract translation: 本发明是由含有有效量的治疗剂的阳离子和/或中性多孔颗粒组成的牙质药物递送组合物，使用牙本质药物递送提供牙科治疗的方法，以及用于鉴定抗炎剂的方法 能够通过牙本质扩散。

公开(公告)号：US09700604B2

公开(公告)日：2017-07-11

申请号：US13906171

申请日：2013-05-30

Applicant: University of Medicine and Dentistry of New Jersey

Inventor： Paola Leone ,  Jeremy Francis

IPC: A61K38/50 ,  C12N15/86 ,  A61K38/52 ,  A61K35/30

CPC classification number: A61K38/50 ,  A61K35/30 ,  A61K38/52 ,  C12N15/86 ,  C12N2750/14141 ,  C12Y305/01015

Abstract: The present invention provides a novel method of treatment for treating brain disorders that manifest oxidative stress by providing targeted populations of neurons with the ability to catabolize the acetylated amino acid derivative, N-acetylaspatic acid (NAA) and further supply extraphysiological levels of ATP to neurons via the targeted expression of the NAA catabolic enzyme aspartoacylase (ASPA) in neurons and astrocytes.

公开(公告)号：US09575073B2

公开(公告)日：2017-02-21

申请号：US13648921

申请日：2012-10-10

Applicant: University of Medicine and Dentistry of New Jersey

Inventor： Kiron M. Das ,  Koushik K. Das ,  Mari Mino-Kenudson

IPC: G01N33/53 ,  G01N33/574 ,  G01N33/68

CPC classification number: G01N33/57438 ,  G01N33/6893 ,  G01N2800/50 ,  G01N2800/52

Abstract: The present invention relates to diagnostic, prognostic and clinical methods of distinguishing high-risk IPMN from more benign IPMN as well as high-grade PanIN and PDAC from low-grade PanIN with moderate sensitivity and very high specificity using Das-1 and related antibodies.

Abstract translation: 本发明涉及使用Das-1和相关抗体，从中等敏感度和非常高的特异性的低等级PanIN区分高风险IPMN与更良性IPMN以及高级PanIN和PDAC的诊断，预后和临床方法。

公开(公告)号：US20030153523A1

公开(公告)日：2003-08-14

申请号：US10295761

申请日：2002-11-15

Applicant: University of Medicine and Dentistry of New Jersey

Inventor： Tariq M. Rana

IPC: A61K048/00 ,  C12Q001/68

CPC classification number: C07C279/12 ,  A61K38/00 ,  C07C271/12 ,  C07C271/20 ,  C07C271/22 ,  C07H21/00 ,  C07K5/0205 ,  C07K5/06026 ,  C07K5/06086 ,  C07K5/081 ,  C07K5/0815 ,  Y02A50/463 ,  Y02A50/465

Abstract: The present invention relates to methods of screening for compounds that bind RNA molecules. In particular, the methods of the invention comprise screening a library of test compounds, each of which is attached to a solid support, with a dye-labeled RNA molecule to form a dye-labeled target RNA:support-attached test compound complex. By virtue of the dye label on the target RNA, the support becomes labeled and can be separated from unlabeled solid supports. The present invention further relates to methods of inhibiting an RNA-protein interaction, to methods of screening for compounds that increase or decrease the production of a protein, and to methods of screening for a compound that is capable of treating or preventing a disease whose progression is associated with an in vivo binding of a test compound to a target RNA.

公开(公告)号：US20020137118A1

公开(公告)日：2002-09-26

申请号：US09935744

申请日：2001-08-24

Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY

Inventor： Masayori Inouye ,  Ujwal Shinde ,  Xuan Fu

IPC: C12Q001/37 ,  C12P021/06

CPC classification number: C12Y304/21062 ,  C07K1/113 ,  C12N9/48 ,  C12N9/54 ,  C12N9/6424 ,  C12Q1/37 ,  C12Y304/16005 ,  C12Y304/21012

Abstract: This invention provides biologically active protein folding intermediates and methods of making and using the same.

Abstract translation: 本发明提供生物活性蛋白质折叠中间体及其制备和使用方法。

公开(公告)号：US20020106767A1

公开(公告)日：2002-08-08

申请号：US09972016

申请日：2001-10-04

Applicant: University of Medicine and Dentistry of New Jersey

Inventor： Tariq M. Rana ,  Natarajan Tamilarasu

IPC: C12P021/06 ,  C12N009/00

CPC classification number: C07K14/005 ,  C07K1/1077 ,  C07K1/113 ,  C07K1/13 ,  C12N2740/16322

Abstract: Site-specific modified proteins and method for producing site-specific modified proteins using amino acid analogs are disclosed. Methods for labeling proteins at a desired site in the presence of nucleophilic side chains, including lysine and cysteine side chains, are also disclosed. Methods for labeling the site-specific modified proteins are also disclosed.

Abstract translation: 公开了位点特异性修饰蛋白质和使用氨基酸类似物产生位点特异性修饰蛋白质的方法。 还公开了在亲核侧链（包括赖氨酸和半胱氨酸侧链）存在下在所需位点标记蛋白质的方法。 还公开了用于标记位点特异性修饰蛋白质的方法。

公开(公告)号：US20140193878A1

公开(公告)日：2014-07-10

申请号：US13932498

申请日：2013-07-01

Applicant: University of Medicine and Dentistry of New Jersey

Inventor： Masayori Inouye ,  Hirofumi Nariya

IPC: C12N9/16

CPC classification number: C12N9/16 ,  C07K14/195

Abstract: A regulated deployment of a toxin gene for developmental programmed cell death in bacteria is described. M. xanthus is demonstrated to have a solitary mazF gene that lacks a cotranscribed antitoxin gene. Deletion of mazF results in elimination of the obligatory cell death during development causing dramatic reduction in spore formation. Surprisingly, MrpC functions as a MazF antitoxin and a mazF transcription activator. Transcription of mrpC and mazF is negatively regulated via MrpC phosphorylation by a Ser/Thr kinase cascade. Various methods of exploiting this novel pathway are described herein.

Abstract translation: 描述了在细菌中发育程序性细胞死亡的毒素基因的调节性部署。 黄曲霉被证明具有缺乏共转录的抗毒素基因的孤立的mazF基因。 mazF的删除导致在发育过程中消除强制性细胞死亡，导致孢子形成的显着减少。 令人惊讶的是，MrpC起MazF抗毒素和mazF转录激活物的作用。 mrpC和mazF的转录通过Ser / Thr激酶级联的MrpC磷酸化负调控。 本文描述了利用这种新途径的各种方法。